Yeda, the Tech Transfer Company of the Weizmann Institute has a patent for glatiramer acetate which is exclusively licensed to Teva. The pharmaceutical is marketed as Copaxone and used to treat multiple schlerosis (MS).
Mylan challenged the validity of the European patent EP 07862888 which, after a 13 day trial has been upheld by Mr Justice Arnold (Patents Court, England and Wales) in Generics (t/a Mylan) v Yeda and Teva  EWHC 1848 (Pat).
For more details on this development, I refer readers to the IPKAT here.
We note that the US patent was recently upheld – see our previous post here for more details.